NeuBase Therapeutics, Inc. - FORM 10-Q - EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - February 14, 2014

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - NeuBase Therapeutics, Inc.Financial_Report.xls
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex31-1.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - NeuBase Therapeutics, Inc.ex31-2.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex32-1.htm
10-Q - QUARTERLY REPORT PURSUANT TO SECTIONS 13 OR 15(D). - NeuBase Therapeutics, Inc.ohr-10q_123113.htm

 
Exhibit 32.2
 
Certification of Principal Financial Officer 
Pursuant to 18 U.S.C Section 1350, 
As Adopted Pursuant to Section 906 of the 
Sarbanes-Oxley Act of 2002
  
Not Filed Pursuant to the Securities Exchange Act of 1934
  
In connection with the Quarterly Report of Ohr Pharmaceutical, Inc. (the “Company” ) on Form 10-Q for the period ending December 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report” ), I, Sam Backenroth , Principal Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:  
     
 
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
  
Dated: February 14, 2014
  
   
/s/ Sam Backenroth
  
Name: Sam Backenroth
  
Title: Principal Financial Officer
  
 
 

NeuBase Therapeutics, Inc. Reports